{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T04:25:57Z","timestamp":1787199957689,"version":"build-2736575974"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Intravenous thrombolysis (IVT) in patients with acute ischemic stroke (AIS) related to dabigatran use requires prior anticoagulation reversal. This study aimed to evaluate the safety and efficacy of IVT following idarucizumab-mediated reversal through a systematic single-arm meta-analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We systematically searched multiple databases. Single-arm studies (\u22655 patients) on idarucizumab-facilitated IVT for dabigatran-related AIS were included. Outcome data from DOAC patients without reversal in the Meinel 2023 cohort (\n                      <jats:italic>n<\/jats:italic>\n                      =\u202f580) served as a descriptive external reference. Pooled proportions for safety (symptomatic intracranial hemorrhage, sICH) and efficacy (90-day good functional outcome, mRS 0\u20132) were calculated using a random-effects GLMM.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Eleven single-arm studies (226 patients) were included. The pooled sICH rate was 5.4% (95% CI 2.6\u201310.6%;\n                      <jats:italic>\u03c4<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      =\u202f0.362,\n                      <jats:italic>Q p<\/jats:italic>\n                      =\u202f0.12). The pooled 90-day good functional outcome rate was 66.6% (95% CI 54.2\u201377.1%;\n                      <jats:italic>\u03c4<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      =\u202f0.116). In the external reference cohort, the sICH rate was 3.1% and the good outcome rate was 42.4%. Due to baseline imbalances and lack of confounder adjustment, descriptive comparisons were hypothesis-generating only. The certainty of evidence was rated very low (GRADE).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Current evidence is insufficient to guide routine clinical practice. However, these findings provide useful effect-size estimates (sICH ~5%, good outcome ~67%) for designing future randomised controlled trials. Multicenter prospective registries or pragmatic RCTs are warranted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fneur.2026.1884021","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T04:15:39Z","timestamp":1787199339000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety and efficacy of idarucizumab-assisted thrombolysis in dabigatran-related acute ischemic stroke: a systematic review and single-arm meta-analysis"],"prefix":"10.3389","volume":"17","author":[{"given":"Xiaoyuan","family":"Guo","sequence":"first","affiliation":[{"name":"Department of Neurology, Dongzhimen Hospital, Beijing University of Chinese Medicine","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Xiong","sequence":"additional","affiliation":[{"name":"Department of Neurology, Dongzhimen Hospital, Beijing University of Chinese Medicine","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenping","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Neurology, Chifeng Municipal Hospital","place":["Chifeng, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Liu","sequence":"additional","affiliation":[{"name":"Acupuncture Department, Huguosi Hospital of Traditional Chinese Medicine Affiliated to Beijing University of Chinese Medicine","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Li","sequence":"additional","affiliation":[{"name":"General Practice Department, Gantang Community Health Service Center","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingbo","family":"Kong","sequence":"additional","affiliation":[{"name":"Department of Neurology, Dongzhimen Hospital, Beijing University of Chinese Medicine","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinxing","family":"Lai","sequence":"additional","affiliation":[{"name":"Department of Neurology, Dongzhimen Hospital, Beijing University of Chinese Medicine","place":["Beijing, China"]},{"name":"Institute for Brain Disorders, Beijing University of Chinese Medicine","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,20]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"I","DOI":"10.1177\/2396987321989865","article-title":"European stroke organisation (ESO) guidelines on intravenous thrombolysis for acute ischaemic stroke","volume":"6","author":"Berge","year":"2021","journal-title":"Eur Stroke J"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1056\/NEJMoa1707278","article-title":"Idarucizumab for dabigatran reversal \u2013 full cohort analysis","volume":"377","author":"Pollack","year":"2017","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.thromres.2023.05.020","article-title":"Idarucizumab for dabigatran reversal: a systematic review and meta-analysis of indications and outcomes","volume":"228","author":"van der Horst","year":"2023","journal-title":"Thromb Res"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"e209862","DOI":"10.1212\/WNL.0000000000209862","article-title":"Thrombolysis after dabigatran reversal for acute ischemic stroke: a national registry-based study and meta-analysis","volume":"103","author":"Theodorou","year":"2024","journal-title":"Neurology"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1001\/jamaneurol.2022.4782","article-title":"Intravenous thrombolysis in patients with ischemic stroke and recent ingestion of direct oral anticoagulants","volume":"80","author":"Meinel","year":"2023","journal-title":"JAMA Neurol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"2836","DOI":"10.1161\/STROKEAHA.125.051384","article-title":"Intravenous thrombolysis in patients with recent intake of direct oral anticoagulants: a target trial analysis and comparison with reversal agent use","volume":"56","author":"Meinel","year":"2025","journal-title":"Stroke"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1177\/23969873221131635","article-title":"Thrombolysis after dabigatran reversal: a nation-wide Italian multicentre study, systematic review and meta-analysis","volume":"8","author":"Romoli","year":"2023","journal-title":"Eur Stroke J"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1161\/STROKEAHA.119.026426","article-title":"Safety of intravenous thrombolysis among patients taking direct oral anticoagulants: a systematic review and meta-analysis","volume":"51","author":"Shahjouei","year":"2020","journal-title":"Stroke"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s40263-021-00792-2","article-title":"Idarucizumab reversal of dabigatran in patients with acute ischemic stroke and intracranial hemorrhage: comparison with non-idarucizumab-treated patients","volume":"35","author":"Frol","year":"2021","journal-title":"CNS Drugs"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"465","DOI":"10.5603\/pjnns.96469","article-title":"Reversing dabigatran effect with idarucizumab to enable intravenous thrombolysis in patients with acute ischaemic stroke \u2013 a single Centre experience","volume":"57","author":"Wlodarczyk","year":"2023","journal-title":"Neurol Neurochir Pol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1161\/STROKEAHA.119.028327","article-title":"Dabigatran reversal before intravenous tenecteplase in acute ischemic stroke","volume":"51","author":"Beharry","year":"2020","journal-title":"Stroke"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1177\/1747493019895654","article-title":"Antagonizing dabigatran by idarucizumab in cases of ischemic stroke or intracranial hemorrhage in Germany\u2014updated series of 120 cases","volume":"15","author":"Kermer","year":"2020","journal-title":"Int J Stroke"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","article-title":"Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of observational studies in epidemiology (MOOSE) group","volume":"283","author":"Stroup","year":"2000","journal-title":"JAMA"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/S0140-6736(98)08020-9","article-title":"Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian acute stroke study investigators","volume":"352","author":"Hacke","year":"1998","journal-title":"Lancet"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1056\/NEJM199512143332401","article-title":"Tissue plasminogen activator for acute ischemic stroke","volume":"333","year":"1995","journal-title":"N Engl J Med"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1161\/01.STR.19.5.604","article-title":"Interobserver agreement for the assessment of handicap in stroke patients","volume":"19","author":"van Swieten","year":"1988","journal-title":"Stroke"},{"key":"ref19","volume-title":"JBI Manual for Evidence Synthesis","author":"Moola","year":"2020"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"3046","DOI":"10.1002\/sim.4040","article-title":"Random effects meta-analysis of event outcome in the framework of the generalized linear mixed model with applications in sparse data","volume":"29","author":"Stijnen","year":"2010","journal-title":"Stat Med"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1136\/jech-2013-203104","article-title":"Meta-analysis of prevalence","volume":"67","author":"Barendregt","year":"2013","journal-title":"J Epidemiol Community Health"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","article-title":"How to perform a meta-analysis with R: a practical tutorial","volume":"22","author":"Balduzzi","year":"2019","journal-title":"Evid Based Ment Health"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"l6890","DOI":"10.1136\/bmj.l6890","article-title":"Synthesis without meta-analysis (SWiM) in systematic reviews: reporting guideline","volume":"368","author":"Campbell","year":"2020","journal-title":"BMJ"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.1016\/j.jstrokecerebrovasdis.2018.05.004","article-title":"Intravenous thrombolysis in patients with acute ischemic stroke after a reversal of dabigatran anticoagulation with idarucizumab: a real-world clinical experience","volume":"27","author":"San\u00e1k","year":"2018","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.3390\/medicina58101355","article-title":"Idarucizumab in dabigatran-treated patients with acute ischemic stroke receiving thrombolytic therapy","volume":"58","author":"Kikule","year":"2022","journal-title":"Medicina (Kaunas)"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/j.jstrokecerebrovasdis.2018.11.029","article-title":"Intravenous thrombolysis in acute ischemic stroke after idarucizumab reversal of dabigatran effect: analysis of the cases from Taiwan","volume":"28","author":"Fang","year":"2019","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1136\/jnnp-2017-316449","article-title":"Intravenous alteplase and endovascular clot retrieval following reversal of dabigatran with idarucizumab","volume":"89","author":"Tse","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1007\/s40263-017-0460-x","article-title":"Idarucizumab in dabigatran-treated patients with acute ischemic stroke receiving alteplase: a systematic review of the available evidence","volume":"31","author":"Pikija","year":"2017","journal-title":"CNS Drugs"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1056\/NEJMoa1607887","article-title":"Andexanet alfa for acute major bleeding associated with factor Xa inhibitors","volume":"375","author":"Connolly","year":"2016","journal-title":"N Engl J Med"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2026.1884021\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T04:15:41Z","timestamp":1787199341000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2026.1884021\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,20]]},"references-count":31,"alternative-id":["10.3389\/fneur.2026.1884021"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2026.1884021","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,20]]},"article-number":"1884021"}}